Results of EORTC trial 26101 presented today at The 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology showed that bevacizumab treatment in patients with progressive glioblastoma, despite prolonged progression-free survival, does not confer a survival advantage.
Prof. Dr. Wolfgang Wick of the Uniklinik Heidelberg and coordinator of this study says, “The future challenge is to identify those patients deriving benefit from that treatment.”
With an annual incidence of approximately five cases per 100,000 persons, gliomas are the most frequently occurring brain tumor in adults.
